Multiple Sclerosis
Roche: VERISMO Study
Open
The VERISMO study is a multi-source, multi-country, noninterventional, longitudinal cohort PAS study on patients with MS who have newly initiated treatment with ocralizumab.
Novartis: Remibrutinib vs. Teriflunomide
Open
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib
Contineum: Pipeline Vista Study
Open
The VISTA Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Oral PIPE-307 as an Adjunctive Treatment in Subjects with Relapsing-Remitting Multiple Sclerosis
Adamas: INROADS Study
Closed
The INROADS study is now enrolling volunteers to help test an investigational study drug for people with MS who have trouble walking. Our researchers want to learn if the investigational medication may help improve walking and become a future treatment option.
Novartis: PASSAGE Study
Closed
The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with Fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety profile of Fingolimod under conditions of routine medical practice.
Closed
The purpose of this observational study is to identify the long-term safety and effectiveness of PLEGRIDY, over approximately a five-year time period. Information on quality of life, side effects, relapses, and disability progression in patients taking PLEGRIDY will be collected. You do not need to come to the clinic for any extra visits as you will see your doctor as part of your regular care. Your participation in the study is voluntary.
Biogen: POP PLEGRIDY® (PEG-Interferon β-1A) Study
TEVA Pharmaceuticals: CONFIDENCE Study
Closed
The purpose of this study is to compare patient medication satisfaction between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone 20 mg/mL once daily (QD) groups. After 6 months of either treatment assignment, all subjects will enter the 6 month extension phase where all subjects will receive Copaxone 40 mg/mL three time a week (TIW). Study participation is 12 months in total and completely voluntary.